ORGS Orgenesis Inc.

Orgenesis Inc is engaged in developing clinical stage technology that with the capacity to induce a shift in developmental fate of cells from liver & converting them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes.

$4.99
As of 07/28/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/01/2013
Outstanding shares:  24,479,751
Average volume:  59,755
Market cap:   $117,013,210
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    68619K204
ISIN:        US68619K2042
Sedol:      BFN4JJ5
Valuation   (See tab for details)
PE ratio:   -1.77
PB ratio:   2.23
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy